Advances on the management strategies for sepsis-induced cardiomyopathy
10.3760/cma.j.issn.1673-4912.2024.10.012
- VernacularTitle:脓毒症心肌病的治疗研究进展
- Author:
Zihui LIU
1
;
Huijie MIAO
;
Yucai ZHANG
Author Information
1. 上海市儿童医院 上海交通大学医学院附属儿童医院重症医学科 200062
- Keywords:
Sepsis-induced cardiomyopathy;
Treatment;
Inotropic drugs;
Extracorporeal life support
- From:
Chinese Pediatric Emergency Medicine
2024;31(10):783-787
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis cardiomyopathy (SIC) is sepsis complicated with heart dysfunction，and its definition，pathogenesis，diagnostic criteria and therapeutic measures have not been well established.The reported prevalence of SIC varied from 10% to 70% and the diagnosis based on the measures of heart function and biological markers.The most important indicator is reduced left heart ejection fraction.Currently，it is believed that SIC should avoid rapid high-dose liquid treatment on the basis of infection treatment.The use of inotropic drugs needs to consider the improvement of myocardial contractility and avoid inducing arrhythmia and adverse effects on vascular resistance.The appropriate timing of extracorporeal membrane oxygenation support is still be challenged.The review focusesd on the fluid management and progress，vasoactive drug therapy and mechanical assistance，and the development of novel targeted drugs in SIC.
